Publications & Patents

Publications & Patents

Total 57건 1 페이지
Publications & Patents 목록
No. 제목
57
Publication

BMC Cancer

2020

AbstractBackgroundWe investigated whether head and neck squamous cell carcinoma (HNSCC) patient-derived xenografts (PDXs) reaffirm patient responses to anti-cancer therapeutics.MethodsTumors from HNSCC patients were transplanted into immunodeficient mice and p…

1일 전 2
56
Publication

EMBO Mol Med

2019

AbstractClinical benefit of ALK tyrosine kinase inhibitors (ALK‐TKIs) in ALK‐rearranged lung cancer has been limited by the inevitable development of acquired resistance, and bypass‐molecular resistance mechanisms remain poorly understood. We in…

1일 전 2
55
Publication

Clin Cancer Res.

2019

AbstractPurpose: Given that osimertinib is the only approved third-generation EGFR-TKI against EGFR activating and resistant T790M mutated non-small cell lung cancer (NSCLC), additional mutant-selective inhibitors with a higher efficacy, especia…

1일 전 2
54
Publication

Lung Cancer

2019

AbstractBackground: With the advance of immunotherapy, treatment of non-small-cell lung cancer (NSCLC) has revolutionized by having anti-PD-1 therapy in front-line setting. In this era of cancer immunotherapy, humanized mouse models which recapitulate hum…

1일 전 2
53
Publication

Sci Rep

2019

AbstractAdequate preclinical model and model establishment procedure are required to accelerate translational research in lung cancer. We streamlined a protocol for establishing patient-derived cells (PDC) and identified effective targeted therapies and novel …

1일 전 2
52
Publication

Ann Oncol

2019

AbstractBackground: Immune checkpoint blockade with Programmed cell death 1 (PD-1)/PD-L1 inhibitors has been effective in various malignancies and is considered as a standard treatment modality for patients with non-small-cell lung cancer (NSCLC). However…

1일 전 2
51
Publication

Journal of Cancer Research and Clinical Oncology

2018

AbstractPurpose: Immune checkpoint inhibitors (ICI) have shown marked responses in patients with non-small cell lung cancer (NSCLC) in clinical trials. However, because such trials comprise cohorts selected based on specific criteria, it is unclear if the…

2일 전 3
50
Publication

Cancer Research

2018

AbstractAnaplastic lymphoma kinase (ALK) inhibitors are highly effective in patients with ALK fusion–positive lung cancer, but acquired resistance invariably emerges. Identification of secondary mutations has received considerable attention, but most…

2일 전 2
49
Publication

Lung Cancer

2018

AbstractBackground: Preclinical models that can better predict therapeutic activity in clinical trials are needed in this era of personalized cancer treatment. Herein, we established genomically and clinically annotated patient-derived xenografts (PDXs) f…

2일 전 2
48
Publication

J Thorac Oncol

2017

AbstractBackground: Anaplastic lymphoma receptor tyrosine kinase gene (ALK) fusion is a distinct molecular subclassification of NSCLC that is targeted by anaplastic lymphoma kinase (ALK) inhibitors. We established a transgenic mouse model that expresses t…

2일 전 3
47
Publication

Oncotarget

2016

AbstractProfilin-like protein in Toxoplasma gondii (TgPLP) is a Toll-like receptor (TLR) agonist. In this study, we investigated whether TgPLP has an adjuvant effect on immune function in autologous whole-tumor-cell vaccine (AWV) treatment. Mice vaccinated wit…

2일 전 3
46
Publication

Oncogenesis

2016

AbstractAberrant fibroblast growth factor receptor (FGFR) activation/expression is a common feature in lung cancer (LC). In this study, we evaluated the antitumor activity of and the mechanisms underlying acquired resistance to two potent selective FGFR inhibi…

2일 전 2
45
Publication

Scientific reports

2016

AbstractTo investigate the expression of programmed death-ligand 1 (PD-L1) and immune checkpoints and their prognostic value for resected head and neck squamous cell cancer (HNSCC). PD-L1 expression on tumor cells (TC) and tumor-infiltrating immune cells (IC),…

2일 전 2
44
Publication

Lung Cancer

2016

AbstractObjectives: The epidermal growth factor receptor (EGFR) abnormalities including amplification, mutation, and overexpression are frequent in non-small cell lung cancer (NSCLC). We investigated in vitro and in vivo antitumor activity of ER2, a novel…

2일 전 2
43
Publication

Oncotarget

2015

AbstractThe purpose of this study was to investigate the clinical activity, safety and predictive biomarkers of dacomitinib, an irreversible pan-HER inhibitor, in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M-ESCC). Patients, wh…

2일 전 2

검색